Efficacy and safety of leuprorelin (Boennuokang^®) plus endocrine therapy in premenopausal women with HR⁺/HER2^- breast cancer.

ABSTRACT:

Background

Leuprorelin shows good efficacy in premenopausal women with hormone receptor-positive (HR⁺)/human epidermal growth factor receptor 2-negative (HER2^-) breast cancer. However, more real-world evidence is required. This real-world study aimed to explore the efficacy and safety of leuprorelin (Boennuokang^®) plus endocrine therapy in premenopausal women with HR⁺/HER2^- breast cancer.

Methods

A total of 229 premenopausal women with HR⁺/HER2^- breast cancer receiving adjuvant leuprorelin plus endocrine therapy were included in this retrospective study. Leuprorelin (Boennuokang^®) was administered 3.75 mg subcutaneously every 28 days following surgery. Endocrine therapy contained aromatas

SUBMITTER: Wu X 

PROVIDER: S-EPMC12267250 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature